Orchard Therapeutics PLC
Greg Crawford is a Senior Scientist at Orchard Therapeutics, specializing in ex vivo autologous gene therapy since September 2021, where hematopoietic stem cells are modified to correct deleterious mutations. Prior to this role, Greg served as a Wellcome Trust ISSF Fellow at Imperial College London from November 2013 to September 2021, focusing on the interplay between allergic and autoimmune diseases, and also worked as a Research Associate assessing immune responses at epithelial barrier sites. Greg's academic journey includes a postdoctoral position at the University of Oxford funded by the MRC Centenary Grant, and a DPhil in Clinical Medicine from the University of Oxford, where research centered on novel genes regulating the immune system. Additionally, Greg supervised undergraduate students in laboratory projects during a tenure at the University of Oxford, emphasizing skills and data management in scientific research.